Background: About a third of patients with inflammatory bowel disease do not respond to
anti-tumour necrosis factor (anti-TNF) therapy, which is challenging. Aim: To review the …

Background The efficacy and safety of vedolizumab in bio-naïve patients with ulcerative
colitis (UC) and Crohn's disease (CD) remain unknown. Aims To perform a meta-analysis …

Background & Aims Clinicians face difficulty in when and in what order to position biologics
and Janus kinase inhibitors in patients with anti-tumor necrosis factor-alpha (TNF) refractory …

Abstract Background and Aims Many observational studies on the use of vedolizumab [VDZ]
in patients with Crohn's disease [CD] and ulcerative colitis [UC] have been published in the …

Background: Prospectively and systematically collected real-world data on vedolizumab are
scarce. We aimed to assess the long-term clinical effectiveness of vedolizumab in …

A treat-to-target (T2T) approach applies the principles of early intervention and tight disease
control to optimise long-term outcomes in Crohn's disease. The Selecting Therapeutic …

Background Optimizing second-line biologic therapies for adult ulcerative colitis (UC) post
first-line failure is essential. Objective Compare second-line biologic therapy efficacy in adult …

Background Data from real-life populations about vedolizumab as first-line biological
therapy for ulcerative colitis (UC) and Crohn's disease (CD) are emerging. Objective To …

Vedolizumab (VDZ), a monoclonal antibody to α4β7 integrin, is available for patients with
moderate-to-severe ulcerative colitis (UC). This study planned to assess the real-world …

Abstract Background and Aim Vedolizumab is a humanized monoclonal antibody that
selectively inhibits the migration of gut‐homing memory T cells into the intestinal submucosa …